Research suggests a potential means of circumventing drug resistance in breast cancer patients (News-Medical-Net)

Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers from The University of Texas M. D. Anderson Cancer Center report in Clinical Cancer Research.

Go here to see the original: 
Research suggests a potential means of circumventing drug resistance in breast cancer patients (News-Medical-Net)